Testhyperlink123: Difference between revisions
Jump to navigation
Jump to search
Guptareeya53 (talk | contribs) No edit summary |
Guptareeya53 (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00054MO G00054MO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00054MO G00054MO] <br> | ||
'''term_in_sentence''' : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]] <br> | '''term_in_sentence''' : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]|[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]|[https://pubmed.ncbi.nlm.nih.gov/10075923 10075923]|[https://pubmed.ncbi.nlm.nih.gov/19054801 19054801]|[https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]|[https://pubmed.ncbi.nlm.nih.gov/31054033 31054033]|[https://pubmed.ncbi.nlm.nih.gov/15229399 15229399]|[https://pubmed.ncbi.nlm.nih.gov/29061785 29061785]|[https://pubmed.ncbi.nlm.nih.gov/16033070 16033070]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]| [https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]|[https://pubmed.ncbi.nlm.nih.gov/9298692 9298692]|[https://pubmed.ncbi.nlm.nih.gov/18607721 18607721]|[https://pubmed.ncbi.nlm.nih.gov/22593503 22593503]|[https://pubmed.ncbi.nlm.nih.gov/25944902 25944902]| [https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]|[https://pubmed.ncbi.nlm.nih.gov/15780091 15780091]|[https://pubmed.ncbi.nlm.nih.gov/20401888 20401888] <br> | ||
'''definition''' : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH: | '''definition''' : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH: 2030970],CHEI:71622 <br> | ||
'''term_xref''' : GTC:G00054MO |GlycoEpitope:EP0012|CID: | '''term_xref''' : GTC:G00054MO |GlycoEpitope:EP0012|CID: 44456859|CHEBI:71622|MESH: 2030970|GlycoMotif:GGM.000022 <br> | ||
'''synonyms''' : SLe(x)|SLe^x|SLex|Slex <br> | '''synonyms''' : SLe(x)|SLe^x|SLex|Slex <br> | ||
'''function''' : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] <br> | '''function''' : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] <br> | ||
| Line 23: | Line 23: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]|[https://pubmed.ncbi.nlm.nih.gov/9730796 9730796]|[https://pubmed.ncbi.nlm.nih.gov/11867833 11867833]|[https://pubmed.ncbi.nlm.nih.gov/9713476 9713476]|[https://pubmed.ncbi.nlm.nih.gov/2819663 2819663]|[https://pubmed.ncbi.nlm.nih.gov/9372327 9372327]|[https://pubmed.ncbi.nlm.nih.gov/9615762 9615762]|[https://pubmed.ncbi.nlm.nih.gov/1352835 1352835]|[https://pubmed.ncbi.nlm.nih.gov/2575680 2575680]|[https://pubmed.ncbi.nlm.nih.gov/9330526 9330526]|[https://pubmed.ncbi.nlm.nih.gov/8753037 8753037]|[https://pubmed.ncbi.nlm.nih.gov/2210805 2210805]|[https://pubmed.ncbi.nlm.nih.gov/12680155 12680155]|[https://pubmed.ncbi.nlm.nih.gov/11974864 11974864]|[https://pubmed.ncbi.nlm.nih.gov/10453898 10453898]|[https://pubmed.ncbi.nlm.nih.gov/2565704 2565704]|[https://pubmed.ncbi.nlm.nih.gov/17144590 17144590] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]|[https://pubmed.ncbi.nlm.nih.gov/9730796 9730796]|[https://pubmed.ncbi.nlm.nih.gov/11867833 11867833]|[https://pubmed.ncbi.nlm.nih.gov/9713476 9713476]|[https://pubmed.ncbi.nlm.nih.gov/2819663 2819663]|[https://pubmed.ncbi.nlm.nih.gov/9372327 9372327]|[https://pubmed.ncbi.nlm.nih.gov/9615762 9615762]|[https://pubmed.ncbi.nlm.nih.gov/1352835 1352835]|[https://pubmed.ncbi.nlm.nih.gov/2575680 2575680]|[https://pubmed.ncbi.nlm.nih.gov/9330526 9330526]|[https://pubmed.ncbi.nlm.nih.gov/8753037 8753037]|[https://pubmed.ncbi.nlm.nih.gov/2210805 2210805]|[https://pubmed.ncbi.nlm.nih.gov/12680155 12680155]|[https://pubmed.ncbi.nlm.nih.gov/11974864 11974864]|[https://pubmed.ncbi.nlm.nih.gov/10453898 10453898]|[https://pubmed.ncbi.nlm.nih.gov/2565704 2565704]|[https://pubmed.ncbi.nlm.nih.gov/17144590 17144590] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GTC:G06597DS|GlycoEpitope:EP0043|CID: | '''term_xref''' : GTC:G06597DS|GlycoEpitope:EP0043|CID: 91855346|CHEBI:147019 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] <br> | '''function''' : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] <br> | ||
| Line 36: | Line 36: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65562ZE G65562ZE] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65562ZE G65562ZE] <br> | ||
'''term_in_sentence''' : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]] <br> | '''term_in_sentence''' : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]|[https://pubmed.ncbi.nlm.nih.gov/31897478 31897478]|[https://pubmed.ncbi.nlm.nih.gov/31719620 31719620]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]|[https://pubmed.ncbi.nlm.nih.gov/31897478 31897478]|[https://pubmed.ncbi.nlm.nih.gov/31719620 31719620]|[https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]|[https://pubmed.ncbi.nlm.nih.gov/25727149 25727149]|[https://pubmed.ncbi.nlm.nih.gov/11523928 11523928]|[https://pubmed.ncbi.nlm.nih.gov/20407596 20407596]|[https://pubmed.ncbi.nlm.nih.gov/25464017 25464017]|[https://pubmed.ncbi.nlm.nih.gov/30864133 30864133]|[https://pubmed.ncbi.nlm.nih.gov/26391208 26391208]|[https://pubmed.ncbi.nlm.nih.gov/19811634 19811634]|[https://pubmed.ncbi.nlm.nih.gov/29796594 29796594]|[https://pubmed.ncbi.nlm.nih.gov/23725156 23725156]|[https://pubmed.ncbi.nlm.nih.gov/8905873 8905873]|[https://pubmed.ncbi.nlm.nih.gov/11192238 11192238]|[https://pubmed.ncbi.nlm.nih.gov/18275089 18275089]|[https://pubmed.ncbi.nlm.nih.gov/27037304 27037304]|[https://pubmed.ncbi.nlm.nih.gov/11949946 11949946]|[https://pubmed.ncbi.nlm.nih.gov/15604091 15604091]|[https://pubmed.ncbi.nlm.nih.gov/24118321 24118321] <br> | ||
'''definition''' : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] <br> | '''definition''' : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000013|GTC:G65562ZE|CID: | '''term_xref''' : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257<br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 81: | Line 81: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]] <br> | '''term_in_sentence''' : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]| [https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]| [https://pubmed.ncbi.nlm.nih.gov/27501865 27501865] <br> | ||
'''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. <br> | '''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 96: | Line 96: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G36123IU G36123IU] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G36123IU G36123IU] <br> | ||
'''term_in_sentence''' : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]] <br> | '''term_in_sentence''' : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]|[https://pubmed.ncbi.nlm.nih.gov/29273237 29273237]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]|[https://pubmed.ncbi.nlm.nih.gov/29273237 29273237]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/31595388 31595388]|[https://pubmed.ncbi.nlm.nih.gov/26617889 26617889]|[https://pubmed.ncbi.nlm.nih.gov/1720922 1720922]|[https://pubmed.ncbi.nlm.nih.gov/15466199 15466199]|[https://pubmed.ncbi.nlm.nih.gov/10971172 10971172]|[https://pubmed.ncbi.nlm.nih.gov/14652017 14652017]|[https://pubmed.ncbi.nlm.nih.gov/8616877 8616877]|[https://pubmed.ncbi.nlm.nih.gov/1543361 1543361]|[https://pubmed.ncbi.nlm.nih.gov/16965854 16965854]|[https://pubmed.ncbi.nlm.nih.gov/21566901 21566901]|[https://pubmed.ncbi.nlm.nih.gov/9269833 9269833]|[https://pubmed.ncbi.nlm.nih.gov/9834267 9834267]|[https://pubmed.ncbi.nlm.nih.gov/24970145 24970145]| [https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]| [https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/30018351 30018351]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]| [https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/28632300 28632300]|[https://pubmed.ncbi.nlm.nih.gov/11308020 11308020]| [https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]|[https://pubmed.ncbi.nlm.nih.gov/17195456 17195456]|[https://pubmed.ncbi.nlm.nih.gov/23567325 23567325]|[https://pubmed.ncbi.nlm.nih.gov/11014575 11014575]|[https://pubmed.ncbi.nlm.nih.gov/2342728 2342728]|[https://pubmed.ncbi.nlm.nih.gov/8575847 8575847]|[https://pubmed.ncbi.nlm.nih.gov/1851822 1851822]|[https://pubmed.ncbi.nlm.nih.gov/11735169 11735169]|[https://pubmed.ncbi.nlm.nih.gov/20960853 20960853]|[https://pubmed.ncbi.nlm.nih.gov/7846011 7846011] <br> | ||
'''definition''' : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] <br> | '''definition''' : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] <br> | ||
'''term_xref''' : GTC:G36123IU|GlycoEpitope:EP0022|CID: | '''term_xref''' : GTC:G36123IU|GlycoEpitope:EP0022|CID: 51351800|CHEBI:61818 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] <br> | '''function''' : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] <br> | ||
| Line 126: | Line 126: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G85497PI G85497PI] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G85497PI G85497PI] <br> | ||
'''term_in_sentence''' : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]] <br> | '''term_in_sentence''' : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]|[https://pubmed.ncbi.nlm.nih.gov/25564944 25564944]|[https://pubmed.ncbi.nlm.nih.gov/30987116 30987116]|[https://pubmed.ncbi.nlm.nih.gov/10778174 10778174]|[https://pubmed.ncbi.nlm.nih.gov/19427293 19427293]|[https://pubmed.ncbi.nlm.nih.gov/24923741 24923741]|[https://pubmed.ncbi.nlm.nih.gov/28092949 28092949]|[https://pubmed.ncbi.nlm.nih.gov/16499901 16499901]|[https://pubmed.ncbi.nlm.nih.gov/10470652 10470652]|[https://pubmed.ncbi.nlm.nih.gov/18787210 18787210]|[https://pubmed.ncbi.nlm.nih.gov/2885312 2885312]|[https://pubmed.ncbi.nlm.nih.gov/16149609 16149609]|[https://pubmed.ncbi.nlm.nih.gov/17003364 17003364]|[https://pubmed.ncbi.nlm.nih.gov/27363517 27363517]|[https://pubmed.ncbi.nlm.nih.gov/15505339 15505339]|[https://pubmed.ncbi.nlm.nih.gov/27990704 27990704]|[https://pubmed.ncbi.nlm.nih.gov/2568298 2568298]|[https://pubmed.ncbi.nlm.nih.gov/20491542 20491542]|[https://pubmed.ncbi.nlm.nih.gov/23572256 23572256]|[https://pubmed.ncbi.nlm.nih.gov/1977666 1977666]|[https://pubmed.ncbi.nlm.nih.gov/9553168 9553168]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]|[https://pubmed.ncbi.nlm.nih.gov/25564944 25564944]|[https://pubmed.ncbi.nlm.nih.gov/30987116 30987116]|[https://pubmed.ncbi.nlm.nih.gov/10778174 10778174]|[https://pubmed.ncbi.nlm.nih.gov/19427293 19427293]|[https://pubmed.ncbi.nlm.nih.gov/24923741 24923741]|[https://pubmed.ncbi.nlm.nih.gov/28092949 28092949]|[https://pubmed.ncbi.nlm.nih.gov/16499901 16499901]|[https://pubmed.ncbi.nlm.nih.gov/10470652 10470652]|[https://pubmed.ncbi.nlm.nih.gov/18787210 18787210]|[https://pubmed.ncbi.nlm.nih.gov/2885312 2885312]|[https://pubmed.ncbi.nlm.nih.gov/16149609 16149609]|[https://pubmed.ncbi.nlm.nih.gov/17003364 17003364]|[https://pubmed.ncbi.nlm.nih.gov/27363517 27363517]|[https://pubmed.ncbi.nlm.nih.gov/15505339 15505339]|[https://pubmed.ncbi.nlm.nih.gov/27990704 27990704]|[https://pubmed.ncbi.nlm.nih.gov/2568298 2568298]|[https://pubmed.ncbi.nlm.nih.gov/20491542 20491542]|[https://pubmed.ncbi.nlm.nih.gov/23572256 23572256]|[https://pubmed.ncbi.nlm.nih.gov/1977666 1977666]|[https://pubmed.ncbi.nlm.nih.gov/9553168 9553168]| [https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]|[https://pubmed.ncbi.nlm.nih.gov/2566639 2566639]|[https://pubmed.ncbi.nlm.nih.gov/14577357 14577357]|[https://pubmed.ncbi.nlm.nih.gov/20960856 20960856]|[https://pubmed.ncbi.nlm.nih.gov/15547746 15547746]|[https://pubmed.ncbi.nlm.nih.gov/9096265 9096265]|[https://pubmed.ncbi.nlm.nih.gov/30639212 30639212]|[https://pubmed.ncbi.nlm.nih.gov/1357195 1357195]|[https://pubmed.ncbi.nlm.nih.gov/1359630 1359630]|[https://pubmed.ncbi.nlm.nih.gov/20181261 20181261]|[https://pubmed.ncbi.nlm.nih.gov/20508065 20508065]|[https://pubmed.ncbi.nlm.nih.gov/2907526 2907526]|[https://pubmed.ncbi.nlm.nih.gov/22624699 22624699]|[https://pubmed.ncbi.nlm.nih.gov/22988836 22988836]|[https://pubmed.ncbi.nlm.nih.gov/17183690 17183690]|[https://pubmed.ncbi.nlm.nih.gov/27188587 27188587]|[https://pubmed.ncbi.nlm.nih.gov/7908065 7908065]|[https://pubmed.ncbi.nlm.nih.gov/10400391 10400391]|[https://pubmed.ncbi.nlm.nih.gov/6137429 6137429]|[https://pubmed.ncbi.nlm.nih.gov/1979260 1979260]|[https://pubmed.ncbi.nlm.nih.gov/2898921 2898921]|[https://pubmed.ncbi.nlm.nih.gov/14736812 14736812]|[https://pubmed.ncbi.nlm.nih.gov/30919971 30919971] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GTC:G85497PI |GlycoEpitope:EP0042|CID: | '''term_xref''' : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] <br> | '''function''' : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] <br> | ||
| Line 140: | Line 140: | ||
'''glycan_dictionary_accession''' : GSD000160 <br> | '''glycan_dictionary_accession''' : GSD000160 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25129BT G25129BT] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25129BT G25129BT] <br> | ||
'''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID: | '''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]|[https://pubmed.ncbi.nlm.nih.gov/30271856 30271856]|[https://pubmed.ncbi.nlm.nih.gov/32684574 32684574]|[https://pubmed.ncbi.nlm.nih.gov/26677875 26677875]|[https://pubmed.ncbi.nlm.nih.gov/23175153 23175153]|[https://pubmed.ncbi.nlm.nih.gov/32525407 32525407]|[https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]|[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]|[https://pubmed.ncbi.nlm.nih.gov/25561682 25561682]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]| [https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]|[https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]| [https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]|[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]|[https://pubmed.ncbi.nlm.nih.gov/31304790 31304790]|[https://pubmed.ncbi.nlm.nih.gov/31642560 31642560]|[https://pubmed.ncbi.nlm.nih.gov/30484221 30484221]|[https://pubmed.ncbi.nlm.nih.gov/30525067 30525067]|[https://pubmed.ncbi.nlm.nih.gov/21161592 21161592]|[https://pubmed.ncbi.nlm.nih.gov/27325407 27325407]|[https://pubmed.ncbi.nlm.nih.gov/28170296 28170296]|[https://pubmed.ncbi.nlm.nih.gov/29637816 29637816]|[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475]|[https://pubmed.ncbi.nlm.nih.gov/31346146 31346146]|[https://pubmed.ncbi.nlm.nih.gov/7648586 7648586]|[https://pubmed.ncbi.nlm.nih.gov/24236059 24236059]|[https://pubmed.ncbi.nlm.nih.gov/21964054 21964054]|[https://pubmed.ncbi.nlm.nih.gov/27456773 27456773]|[https://pubmed.ncbi.nlm.nih.gov/30558911 30558911]|[https://pubmed.ncbi.nlm.nih.gov/21559451 21559451]|[https://pubmed.ncbi.nlm.nih.gov/29312455 29312455]|[https://pubmed.ncbi.nlm.nih.gov/27549315 27549315]|[https://pubmed.ncbi.nlm.nih.gov/30599359 30599359]|[https://pubmed.ncbi.nlm.nih.gov/6141938 6141938]|[https://pubmed.ncbi.nlm.nih.gov/28883415 28883415]|[https://pubmed.ncbi.nlm.nih.gov/30733757 30733757]|[https://pubmed.ncbi.nlm.nih.gov/26041528 26041528]|[https://pubmed.ncbi.nlm.nih.gov/16643871 16643871] <br> | ||
'''definition''' : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] <br> | '''definition''' : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] <br> | ||
'''term_xref''' : GTC:G25129BT|GlycoEpitope:EP0039|CID: | '''term_xref''' : GTC:G25129BT|GlycoEpitope:EP0039|CID: 91855781|CHEBI:149071|GlycoMotif:GGM.000079 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 155: | Line 155: | ||
'''glycan_dictionary_accession''' : GSD000161 <br> | '''glycan_dictionary_accession''' : GSD000161 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G84263XI G84263XI] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G84263XI G84263XI] <br> | ||
'''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID: | '''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27845370 27845370]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27845370 27845370]|[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]|[https://pubmed.ncbi.nlm.nih.gov/26295543 26295543]|[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]|[https://pubmed.ncbi.nlm.nih.gov/25978997 25978997]|[https://pubmed.ncbi.nlm.nih.gov/30296654 30296654]|[https://pubmed.ncbi.nlm.nih.gov/25853231 25853231]|[https://pubmed.ncbi.nlm.nih.gov/24862940 24862940]|[https://pubmed.ncbi.nlm.nih.gov/31243630 31243630]|[https://pubmed.ncbi.nlm.nih.gov/28736232 28736232]|[https://pubmed.ncbi.nlm.nih.gov/22895512 22895512]|[https://pubmed.ncbi.nlm.nih.gov/24578244 24578244]|[https://pubmed.ncbi.nlm.nih.gov/29478902 29478902]|[https://pubmed.ncbi.nlm.nih.gov/23574147 23574147]|[https://pubmed.ncbi.nlm.nih.gov/23768762 23768762]|[https://pubmed.ncbi.nlm.nih.gov/27797400 27797400]| [https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]|[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]|[https://pubmed.ncbi.nlm.nih.gov/25123923 25123923]|[https://pubmed.ncbi.nlm.nih.gov/22924692 22924692]|[https://pubmed.ncbi.nlm.nih.gov/22665977 22665977]|[https://pubmed.ncbi.nlm.nih.gov/23330736 23330736]|[https://pubmed.ncbi.nlm.nih.gov/31831622 31831622]|[https://pubmed.ncbi.nlm.nih.gov/31916611 31916611]| [https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/16033656 16033656]|[https://pubmed.ncbi.nlm.nih.gov/24866102 24866102]| [https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]| [https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]|[https://pubmed.ncbi.nlm.nih.gov/26940129 26940129]| [https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]|[https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]|[https://pubmed.ncbi.nlm.nih.gov/23301556 23301556]|[https://pubmed.ncbi.nlm.nih.gov/27836003 27836003]|[https://pubmed.ncbi.nlm.nih.gov/19118716 19118716]|[https://pubmed.ncbi.nlm.nih.gov/24550271 24550271]|[https://pubmed.ncbi.nlm.nih.gov/32988880 32988880]|[https://pubmed.ncbi.nlm.nih.gov/22743677 22743677]|[https://pubmed.ncbi.nlm.nih.gov/20683402 20683402]|[https://pubmed.ncbi.nlm.nih.gov/17062733 17062733]|[https://pubmed.ncbi.nlm.nih.gov/23570331 23570331]|[https://pubmed.ncbi.nlm.nih.gov/30310530 30310530]|[https://pubmed.ncbi.nlm.nih.gov/31545316 31545316]|[https://pubmed.ncbi.nlm.nih.gov/23509763 23509763]|[https://pubmed.ncbi.nlm.nih.gov/24364909 24364909]|[https://pubmed.ncbi.nlm.nih.gov/18273440 18273440]|[https://pubmed.ncbi.nlm.nih.gov/28985528 28985528]|[https://pubmed.ncbi.nlm.nih.gov/22266579 22266579] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GTC:G84263XI|GlycoEpitope:EP0044|CID: | '''term_xref''' : GTC:G84263XI|GlycoEpitope:EP0044|CID:91845478|CHEBI:154843 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 186: | Line 186: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00031MO G00031MO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00031MO G00031MO] <br> | ||
'''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br> | '''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br> | ||
'''publication''' : 723127|[https://pubmed.ncbi.nlm.nih.gov/19505650 19505650]|[https://pubmed.ncbi.nlm.nih.gov/31527246 31527246]|[https://pubmed.ncbi.nlm.nih.gov/28113048 28113048]|[https://pubmed.ncbi.nlm.nih.gov/25868857 25868857]|[https://pubmed.ncbi.nlm.nih.gov/26731525 26731525]|[https://pubmed.ncbi.nlm.nih.gov/22994493 22994493]|[https://pubmed.ncbi.nlm.nih.gov/3849428 3849428]|[https://pubmed.ncbi.nlm.nih.gov/25589241 25589241]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/723127 723127]|[https://pubmed.ncbi.nlm.nih.gov/19505650 19505650]|[https://pubmed.ncbi.nlm.nih.gov/31527246 31527246]|[https://pubmed.ncbi.nlm.nih.gov/28113048 28113048]|[https://pubmed.ncbi.nlm.nih.gov/25868857 25868857]|[https://pubmed.ncbi.nlm.nih.gov/26731525 26731525]|[https://pubmed.ncbi.nlm.nih.gov/22994493 22994493]|[https://pubmed.ncbi.nlm.nih.gov/3849428 3849428]|[https://pubmed.ncbi.nlm.nih.gov/25589241 25589241]|[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/26615524 26615524]|[https://pubmed.ncbi.nlm.nih.gov/26136575 26136575]|[https://pubmed.ncbi.nlm.nih.gov/19671663 19671663]|[https://pubmed.ncbi.nlm.nih.gov/18551603 18551603]|[https://pubmed.ncbi.nlm.nih.gov/11160729 11160729]|[https://pubmed.ncbi.nlm.nih.gov/22261839 22261839]|[https://pubmed.ncbi.nlm.nih.gov/30758913 30758913]|[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]|[https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/24998850 24998850]|[https://pubmed.ncbi.nlm.nih.gov/1654819 1654819]|[https://pubmed.ncbi.nlm.nih.gov/28039910 28039910]|[https://pubmed.ncbi.nlm.nih.gov/29206210 29206210]|[https://pubmed.ncbi.nlm.nih.gov/32404521 32404521]|[https://pubmed.ncbi.nlm.nih.gov/10555041 10555041]|[https://pubmed.ncbi.nlm.nih.gov/26517398 26517398]|[https://pubmed.ncbi.nlm.nih.gov/2446015 2446015]|[https://pubmed.ncbi.nlm.nih.gov/2998768 2998768]|[https://pubmed.ncbi.nlm.nih.gov/3026642 3026642]|[https://pubmed.ncbi.nlm.nih.gov/18812503 18812503]|[https://pubmed.ncbi.nlm.nih.gov/6092664 6092664]|[https://pubmed.ncbi.nlm.nih.gov/2153691 2153691]|[https://pubmed.ncbi.nlm.nih.gov/8709258 8709258]|[https://pubmed.ncbi.nlm.nih.gov/3009889 3009889]|[https://pubmed.ncbi.nlm.nih.gov/15109748 15109748]| [https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/31787742 31787742]|[https://pubmed.ncbi.nlm.nih.gov/27433780 27433780]|[https://pubmed.ncbi.nlm.nih.gov/26017382 26017382]|[https://pubmed.ncbi.nlm.nih.gov/24048785 24048785]|[https://pubmed.ncbi.nlm.nih.gov/26735515 26735515]|[https://pubmed.ncbi.nlm.nih.gov/9224657 9224657]|[https://pubmed.ncbi.nlm.nih.gov/26061652 26061652]|[https://pubmed.ncbi.nlm.nih.gov/29343574 29343574]| [https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]|[https://pubmed.ncbi.nlm.nih.gov/23805194 23805194]|[https://pubmed.ncbi.nlm.nih.gov/26751495 26751495]|[https://pubmed.ncbi.nlm.nih.gov/22023388 22023388]|[https://pubmed.ncbi.nlm.nih.gov/15381338 15381338]|[https://pubmed.ncbi.nlm.nih.gov/8249277 8249277]|[https://pubmed.ncbi.nlm.nih.gov/3023660 3023660]|[https://pubmed.ncbi.nlm.nih.gov/25866902 25866902] <br> | ||
'''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br> | '''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br> | ||
'''term_xref''' : GTC:G00031MO|GlycoEpitope:EP0020|CID: | '''term_xref''' : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009 <br> | ||
'''synonyms''' : TF antigen <br> | '''synonyms''' : TF antigen <br> | ||
'''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br> | '''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br> | ||
| Line 201: | Line 201: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]] <br> | '''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]|[https://pubmed.ncbi.nlm.nih.gov/17951374 17951374]|[https://pubmed.ncbi.nlm.nih.gov/28880909 28880909]|[https://pubmed.ncbi.nlm.nih.gov/9177699 9177699]|[https://pubmed.ncbi.nlm.nih.gov/9760189 9760189]|[https://pubmed.ncbi.nlm.nih.gov/12322961 12322961]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/2492275 2492275]|[https://pubmed.ncbi.nlm.nih.gov/3402460 3402460]|[https://pubmed.ncbi.nlm.nih.gov/2361735 2361735]|[https://pubmed.ncbi.nlm.nih.gov/6525453 6525453]|[https://pubmed.ncbi.nlm.nih.gov/27730440 27730440]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/25365149 25365149]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29875690 29875690]|[https://pubmed.ncbi.nlm.nih.gov/29479898 29479898]|[https://pubmed.ncbi.nlm.nih.gov/9134426 9134426]|[https://pubmed.ncbi.nlm.nih.gov/30943309 30943309]|[https://pubmed.ncbi.nlm.nih.gov/3546284 3546284]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30624066 30624066]|[https://pubmed.ncbi.nlm.nih.gov/30537828 30537828]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/29311294 29311294]|[https://pubmed.ncbi.nlm.nih.gov/12852965 12852965]|[https://pubmed.ncbi.nlm.nih.gov/3015940 3015940]|[https://pubmed.ncbi.nlm.nih.gov/1907570 1907570]|[https://pubmed.ncbi.nlm.nih.gov/29137999 29137999]|[https://pubmed.ncbi.nlm.nih.gov/29359131 29359131]|[https://pubmed.ncbi.nlm.nih.gov/29858715 29858715]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31829566 31829566]|[https://pubmed.ncbi.nlm.nih.gov/8381405 8381405]|[https://pubmed.ncbi.nlm.nih.gov/26929217 26929217]|[https://pubmed.ncbi.nlm.nih.gov/20662591 20662591]|[https://pubmed.ncbi.nlm.nih.gov/30612270 30612270]|[https://pubmed.ncbi.nlm.nih.gov/3089784 3089784]|[https://pubmed.ncbi.nlm.nih.gov/28186213 28186213]|[https://pubmed.ncbi.nlm.nih.gov/3427034 3427034]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/27354006 27354006]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/7496138 7496138]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]|[https://pubmed.ncbi.nlm.nih.gov/17951374 17951374]|[https://pubmed.ncbi.nlm.nih.gov/28880909 28880909]|[https://pubmed.ncbi.nlm.nih.gov/9177699 9177699]|[https://pubmed.ncbi.nlm.nih.gov/9760189 9760189]|[https://pubmed.ncbi.nlm.nih.gov/12322961 12322961]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/2492275 2492275]|[https://pubmed.ncbi.nlm.nih.gov/3402460 3402460]|[https://pubmed.ncbi.nlm.nih.gov/2361735 2361735]|[https://pubmed.ncbi.nlm.nih.gov/6525453 6525453]|[https://pubmed.ncbi.nlm.nih.gov/27730440 27730440]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/25365149 25365149]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29875690 29875690]|[https://pubmed.ncbi.nlm.nih.gov/29479898 29479898]|[https://pubmed.ncbi.nlm.nih.gov/9134426 9134426]|[https://pubmed.ncbi.nlm.nih.gov/30943309 30943309]|[https://pubmed.ncbi.nlm.nih.gov/3546284 3546284]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30624066 30624066]|[https://pubmed.ncbi.nlm.nih.gov/30537828 30537828]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/29311294 29311294]|[https://pubmed.ncbi.nlm.nih.gov/12852965 12852965]|[https://pubmed.ncbi.nlm.nih.gov/3015940 3015940]|[https://pubmed.ncbi.nlm.nih.gov/1907570 1907570]|[https://pubmed.ncbi.nlm.nih.gov/29137999 29137999]|[https://pubmed.ncbi.nlm.nih.gov/29359131 29359131]|[https://pubmed.ncbi.nlm.nih.gov/29858715 29858715]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31829566 31829566]|[https://pubmed.ncbi.nlm.nih.gov/8381405 8381405]|[https://pubmed.ncbi.nlm.nih.gov/26929217 26929217]|[https://pubmed.ncbi.nlm.nih.gov/20662591 20662591]|[https://pubmed.ncbi.nlm.nih.gov/30612270 30612270]|[https://pubmed.ncbi.nlm.nih.gov/3089784 3089784]|[https://pubmed.ncbi.nlm.nih.gov/28186213 28186213]|[https://pubmed.ncbi.nlm.nih.gov/3427034 3427034]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/27354006 27354006]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/7496138 7496138]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/29031301 29031301]|[https://pubmed.ncbi.nlm.nih.gov/9448855 9448855]|[https://pubmed.ncbi.nlm.nih.gov/3979385 3979385]|[https://pubmed.ncbi.nlm.nih.gov/27722599 27722599]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28002670 28002670]|[https://pubmed.ncbi.nlm.nih.gov/28991403 28991403]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]|[https://pubmed.ncbi.nlm.nih.gov/25154914 25154914]|[https://pubmed.ncbi.nlm.nih.gov/22490318 22490318]|[https://pubmed.ncbi.nlm.nih.gov/22430811 22430811]|[https://pubmed.ncbi.nlm.nih.gov/1463783 1463783]|[https://pubmed.ncbi.nlm.nih.gov/18803208 18803208]|[https://pubmed.ncbi.nlm.nih.gov/7881173 7881173]|[https://pubmed.ncbi.nlm.nih.gov/7697655 7697655]|[https://pubmed.ncbi.nlm.nih.gov/7240157 7240157]|[https://pubmed.ncbi.nlm.nih.gov/1768292 1768292] <br> | ||
'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 215: | Line 215: | ||
'''glycan_dictionary_accession''' : GSD000165 <br> | '''glycan_dictionary_accession''' : GSD000165 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID: | '''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8274017 8274017]| [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]| [https://pubmed.ncbi.nlm.nih.gov/6317691 6317691]|[https://pubmed.ncbi.nlm.nih.gov/23668542 23668542]| [https://pubmed.ncbi.nlm.nih.gov/6088518 6088518]|[https://pubmed.ncbi.nlm.nih.gov/21495009 21495009]|[https://pubmed.ncbi.nlm.nih.gov/1457971 1457971]|[https://pubmed.ncbi.nlm.nih.gov/1783599 1783599]|[https://pubmed.ncbi.nlm.nih.gov/10988252 10988252]|[https://pubmed.ncbi.nlm.nih.gov/11425798 11425798]|[https://pubmed.ncbi.nlm.nih.gov/7522229 7522229]|[https://pubmed.ncbi.nlm.nih.gov/2574992 2574992]|[https://pubmed.ncbi.nlm.nih.gov/3730425 3730425]|[https://pubmed.ncbi.nlm.nih.gov/10200178 10200178]|[https://pubmed.ncbi.nlm.nih.gov/2939068 2939068]|[https://pubmed.ncbi.nlm.nih.gov/21584695 21584695]| [https://pubmed.ncbi.nlm.nih.gov/7524670 7524670]|[https://pubmed.ncbi.nlm.nih.gov/7682847 7682847]|[https://pubmed.ncbi.nlm.nih.gov/2930192 2930192]|[https://pubmed.ncbi.nlm.nih.gov/1726466 1726466]|[https://pubmed.ncbi.nlm.nih.gov/9881746 9881746]|[https://pubmed.ncbi.nlm.nih.gov/11068879 11068879]|[https://pubmed.ncbi.nlm.nih.gov/6704968 6704968]|[https://pubmed.ncbi.nlm.nih.gov/2302846 2302846]| [https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]| [https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]|[https://pubmed.ncbi.nlm.nih.gov/11051207 11051207]|[https://pubmed.ncbi.nlm.nih.gov/10220588 10220588]|[https://pubmed.ncbi.nlm.nih.gov/2813359 2813359]|[https://pubmed.ncbi.nlm.nih.gov/2174368 2174368]|[https://pubmed.ncbi.nlm.nih.gov/21755550 21755550]|[https://pubmed.ncbi.nlm.nih.gov/3571208 3571208]|[https://pubmed.ncbi.nlm.nih.gov/1929437 1929437]|[https://pubmed.ncbi.nlm.nih.gov/3681300 3681300]|[https://pubmed.ncbi.nlm.nih.gov/6581225 6581225]|[https://pubmed.ncbi.nlm.nih.gov/3364983 3364983]|[https://pubmed.ncbi.nlm.nih.gov/2902877 2902877]|[https://pubmed.ncbi.nlm.nih.gov/2297756 2297756]|[https://pubmed.ncbi.nlm.nih.gov/1315684 1315684]|[https://pubmed.ncbi.nlm.nih.gov/6830758 6830758]|[https://pubmed.ncbi.nlm.nih.gov/1998670 1998670] <br> | ||
'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | ||
'''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html <br> | '''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html <br> | ||
| Line 230: | Line 230: | ||
'''glycan_dictionary_accession''' : GSD000166 <br> | '''glycan_dictionary_accession''' : GSD000166 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID: | '''term_in_sentence''' : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br> | ||
'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. <br> | '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 246: | Line 246: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57321FI G57321FI] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57321FI G57321FI] <br> | ||
'''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br> | '''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27679419 27679419]|[https://pubmed.ncbi.nlm.nih.gov/31938254 31938254]|[https://pubmed.ncbi.nlm.nih.gov/30637914 30637914]|[https://pubmed.ncbi.nlm.nih.gov/24643043 24643043]|[https://pubmed.ncbi.nlm.nih.gov/31225574 31225574]|[https://pubmed.ncbi.nlm.nih.gov/21259410 21259410]|[https://pubmed.ncbi.nlm.nih.gov/31742337 31742337]|[https://pubmed.ncbi.nlm.nih.gov/28514044 28514044]|[https://pubmed.ncbi.nlm.nih.gov/33014816 33014816]|[https://pubmed.ncbi.nlm.nih.gov/28708980 28708980]|[https://pubmed.ncbi.nlm.nih.gov/27432485 27432485]|[https://pubmed.ncbi.nlm.nih.gov/33050853 33050853]|[https://pubmed.ncbi.nlm.nih.gov/26045765 26045765]|[https://pubmed.ncbi.nlm.nih.gov/27542280 27542280]|[https://pubmed.ncbi.nlm.nih.gov/24411673 24411673]|[https://pubmed.ncbi.nlm.nih.gov/27760846 27760846]|[https://pubmed.ncbi.nlm.nih.gov/30115016 30115016]|[https://pubmed.ncbi.nlm.nih.gov/1410473 1410473]|[https://pubmed.ncbi.nlm.nih.gov/29802864 29802864]|[https://pubmed.ncbi.nlm.nih.gov/29669308 29669308]|[https://pubmed.ncbi.nlm.nih.gov/29251002 29251002]|[https://pubmed.ncbi.nlm.nih.gov/32541028 32541028]|[https://pubmed.ncbi.nlm.nih.gov/31019509 31019509]|[https://pubmed.ncbi.nlm.nih.gov/1582597 1582597]|[https://pubmed.ncbi.nlm.nih.gov/2981150 2981150]|[https://pubmed.ncbi.nlm.nih.gov/10842187 10842187]|[https://pubmed.ncbi.nlm.nih.gov/29638123 29638123]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27679419 27679419]|[https://pubmed.ncbi.nlm.nih.gov/31938254 31938254]|[https://pubmed.ncbi.nlm.nih.gov/30637914 30637914]|[https://pubmed.ncbi.nlm.nih.gov/24643043 24643043]|[https://pubmed.ncbi.nlm.nih.gov/31225574 31225574]|[https://pubmed.ncbi.nlm.nih.gov/21259410 21259410]|[https://pubmed.ncbi.nlm.nih.gov/31742337 31742337]|[https://pubmed.ncbi.nlm.nih.gov/28514044 28514044]|[https://pubmed.ncbi.nlm.nih.gov/33014816 33014816]|[https://pubmed.ncbi.nlm.nih.gov/28708980 28708980]|[https://pubmed.ncbi.nlm.nih.gov/27432485 27432485]|[https://pubmed.ncbi.nlm.nih.gov/33050853 33050853]|[https://pubmed.ncbi.nlm.nih.gov/26045765 26045765]|[https://pubmed.ncbi.nlm.nih.gov/27542280 27542280]|[https://pubmed.ncbi.nlm.nih.gov/24411673 24411673]|[https://pubmed.ncbi.nlm.nih.gov/27760846 27760846]|[https://pubmed.ncbi.nlm.nih.gov/30115016 30115016]|[https://pubmed.ncbi.nlm.nih.gov/1410473 1410473]|[https://pubmed.ncbi.nlm.nih.gov/29802864 29802864]|[https://pubmed.ncbi.nlm.nih.gov/29669308 29669308]|[https://pubmed.ncbi.nlm.nih.gov/29251002 29251002]|[https://pubmed.ncbi.nlm.nih.gov/32541028 32541028]|[https://pubmed.ncbi.nlm.nih.gov/31019509 31019509]|[https://pubmed.ncbi.nlm.nih.gov/1582597 1582597]|[https://pubmed.ncbi.nlm.nih.gov/2981150 2981150]|[https://pubmed.ncbi.nlm.nih.gov/10842187 10842187]|[https://pubmed.ncbi.nlm.nih.gov/29638123 29638123]| [https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/1510031 1510031]|[https://pubmed.ncbi.nlm.nih.gov/19372570 19372570]|[https://pubmed.ncbi.nlm.nih.gov/20641477 20641477]| [https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/27856425 27856425]|[https://pubmed.ncbi.nlm.nih.gov/23814067 23814067]|[https://pubmed.ncbi.nlm.nih.gov/28068458 28068458]| [https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/8174100 8174100]|[https://pubmed.ncbi.nlm.nih.gov/10571017 10571017]|[https://pubmed.ncbi.nlm.nih.gov/27453399 27453399]|[https://pubmed.ncbi.nlm.nih.gov/1727666 1727666]|[https://pubmed.ncbi.nlm.nih.gov/23740330 23740330] <br> | ||
'''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356, | '''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] <br> | ||
'''term_xref''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356| | '''term_xref''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br> | '''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br> | ||
| Line 261: | Line 261: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br> | '''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24992960 24992960]|[https://pubmed.ncbi.nlm.nih.gov/27025342 27025342]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/29456020 29456020]|[https://pubmed.ncbi.nlm.nih.gov/26914862 26914862]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26299345 26299345]|[https://pubmed.ncbi.nlm.nih.gov/28981809 28981809]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/2211710 2211710]|[https://pubmed.ncbi.nlm.nih.gov/23461434 23461434]|[https://pubmed.ncbi.nlm.nih.gov/18327885 18327885]|[https://pubmed.ncbi.nlm.nih.gov/15264862 15264862]|[https://pubmed.ncbi.nlm.nih.gov/22954207 22954207]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26537865 26537865]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24992960 24992960]|[https://pubmed.ncbi.nlm.nih.gov/27025342 27025342]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/29456020 29456020]|[https://pubmed.ncbi.nlm.nih.gov/26914862 26914862]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26299345 26299345]|[https://pubmed.ncbi.nlm.nih.gov/28981809 28981809]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/2211710 2211710]|[https://pubmed.ncbi.nlm.nih.gov/23461434 23461434]|[https://pubmed.ncbi.nlm.nih.gov/18327885 18327885]|[https://pubmed.ncbi.nlm.nih.gov/15264862 15264862]|[https://pubmed.ncbi.nlm.nih.gov/22954207 22954207]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26537865 26537865]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/28129130 28129130]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/8068017 8068017]|[https://pubmed.ncbi.nlm.nih.gov/7783116 7783116]|[https://pubmed.ncbi.nlm.nih.gov/3857231 3857231]|[https://pubmed.ncbi.nlm.nih.gov/20540518 20540518]|[https://pubmed.ncbi.nlm.nih.gov/1706936 1706936]|[https://pubmed.ncbi.nlm.nih.gov/2430615 2430615]|[https://pubmed.ncbi.nlm.nih.gov/8078981 8078981]|[https://pubmed.ncbi.nlm.nih.gov/2211711 2211711]|[https://pubmed.ncbi.nlm.nih.gov/6767476 6767476]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/2597120 2597120]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/20619452 20619452]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/1924399 1924399]|[https://pubmed.ncbi.nlm.nih.gov/6643471 6643471]|[https://pubmed.ncbi.nlm.nih.gov/31809011 31809011]|[https://pubmed.ncbi.nlm.nih.gov/30042045 30042045]|[https://pubmed.ncbi.nlm.nih.gov/2477056 2477056]|[https://pubmed.ncbi.nlm.nih.gov/7882496 7882496]|[https://pubmed.ncbi.nlm.nih.gov/2430614 2430614]| [https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/2426141 2426141]|[https://pubmed.ncbi.nlm.nih.gov/2065052 2065052]|[https://pubmed.ncbi.nlm.nih.gov/28988716 28988716]|[https://pubmed.ncbi.nlm.nih.gov/31144994 31144994]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215] <br> | ||
'''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 276: | Line 276: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]] <br> | '''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/16973123 16973123]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/16973123 16973123]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/31322324 31322324]|[https://pubmed.ncbi.nlm.nih.gov/15044389 15044389]|[https://pubmed.ncbi.nlm.nih.gov/16372382 16372382]| [https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8299583 8299583]|[https://pubmed.ncbi.nlm.nih.gov/1555586 1555586]|[https://pubmed.ncbi.nlm.nih.gov/7509658 7509658]|[https://pubmed.ncbi.nlm.nih.gov/1569060 1569060]|[https://pubmed.ncbi.nlm.nih.gov/16261636 16261636] <br> | ||
'''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252] Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. <br> | '''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252] Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. <br> | ||
'''term_xref''' : CHEBI:156252 <br> | '''term_xref''' : CHEBI:156252 <br> | ||
| Line 306: | Line 306: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]] <br> | '''term_in_sentence''' : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]|[https://pubmed.ncbi.nlm.nih.gov/31964828 31964828]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18642129 18642129]|[https://pubmed.ncbi.nlm.nih.gov/31964828 31964828]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/27936604 27936604]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/21538882 21538882]|[https://pubmed.ncbi.nlm.nih.gov/7579793 7579793]|[https://pubmed.ncbi.nlm.nih.gov/7613477 7613477]|[https://pubmed.ncbi.nlm.nih.gov/2223825 2223825]|[https://pubmed.ncbi.nlm.nih.gov/3539023 3539023]|[https://pubmed.ncbi.nlm.nih.gov/3674882 3674882] <br> | ||
'''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. <br> | '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : Appears in human serotransferrin.[PMID: | '''function''' : Appears in human serotransferrin.[PMID: [https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]] <br> | ||
'''disease_associations''' : <br> | '''disease_associations''' : <br> | ||
'''wikipedia''' : <br> | '''wikipedia''' : <br> | ||
| Line 338: | Line 338: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1735443 1735443] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1735443 1735443] <br> | ||
'''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br> | '''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br> | ||
'''term_xref''' : GlycoEpitope:EP0092|GTC:G74578MX|CID: | '''term_xref''' : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 <br> | ||
'''synonyms''' : trifucosyl-Leb antigen <br> | '''synonyms''' : trifucosyl-Leb antigen <br> | ||
'''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br> | '''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br> | ||
| Line 350: | Line 350: | ||
'''glycan_dictionary_accession''' : GSD000174 <br> | '''glycan_dictionary_accession''' : GSD000174 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74917JX G74917JX] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G74917JX G74917JX] <br> | ||
'''term_in_sentence''' : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID: | '''term_in_sentence''' : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]|[https://pubmed.ncbi.nlm.nih.gov/2426269 2426269] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]|[https://pubmed.ncbi.nlm.nih.gov/2426269 2426269] <br> | ||
'''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br> | '''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br> | ||
'''term_xref''' : GlycoEpitope: EP0094|GTC:G74917JX|CID: | '''term_xref''' : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332 <br> | ||
'''synonyms''' : trifucosyl Ley <br> | '''synonyms''' : trifucosyl Ley <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 381: | Line 381: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709] <br> | '''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6469957 6469957]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/21138277 21138277]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/10782293 10782293]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/20067809 20067809]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/8797382 8797382]|[https://pubmed.ncbi.nlm.nih.gov/16877748 16877748]|[https://pubmed.ncbi.nlm.nih.gov/19131698 19131698]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/24669823 24669823]|[https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6469957 6469957]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/21138277 21138277]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/10782293 10782293]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/20067809 20067809]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/8797382 8797382]|[https://pubmed.ncbi.nlm.nih.gov/16877748 16877748]|[https://pubmed.ncbi.nlm.nih.gov/19131698 19131698]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/24669823 24669823]|[https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/2121479 2121479]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/32209427 32209427]|[https://pubmed.ncbi.nlm.nih.gov/32737218 32737218]|[https://pubmed.ncbi.nlm.nih.gov/33245334 33245334]|[https://pubmed.ncbi.nlm.nih.gov/26927318 26927318]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/26321095 26321095]|[https://pubmed.ncbi.nlm.nih.gov/30463578 30463578]|[https://pubmed.ncbi.nlm.nih.gov/31455764 31455764]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/31266306 31266306]|[https://pubmed.ncbi.nlm.nih.gov/29782424 29782424]|[https://pubmed.ncbi.nlm.nih.gov/31247951 31247951]|[https://pubmed.ncbi.nlm.nih.gov/30487799 30487799]|[https://pubmed.ncbi.nlm.nih.gov/2049094 2049094]|[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832] <br> | ||
'''definition''' : A glycan with three sialic acid components. <br> | '''definition''' : A glycan with three sialic acid components. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 410: | Line 410: | ||
'''glycan_dictionary_accession''' : GSD000178 <br> | '''glycan_dictionary_accession''' : GSD000178 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID: | '''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br> | ||
'''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br> | '''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 426: | Line 426: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br> | '''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]| [https://pubmed.ncbi.nlm.nih.gov/27501865 27501865] |[https://pubmed.ncbi.nlm.nih.gov/10998266 10998266]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/8900952 8900952] <br> | ||
'''definition''' : A triantennry glycan with three sialic acid components. <br> | '''definition''' : A triantennry glycan with three sialic acid components. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 442: | Line 442: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27834790 27834790]|[https://pubmed.ncbi.nlm.nih.gov/31523406 31523406]|[https://pubmed.ncbi.nlm.nih.gov/29978304 29978304]|[https://pubmed.ncbi.nlm.nih.gov/29575185 29575185]|[https://pubmed.ncbi.nlm.nih.gov/27326514 27326514]|[https://pubmed.ncbi.nlm.nih.gov/29029114 29029114]|[https://pubmed.ncbi.nlm.nih.gov/32450200 32450200]|[https://pubmed.ncbi.nlm.nih.gov/29432937 29432937]|[https://pubmed.ncbi.nlm.nih.gov/31906402 31906402]|[https://pubmed.ncbi.nlm.nih.gov/28739428 28739428]|[https://pubmed.ncbi.nlm.nih.gov/29298123 29298123]|[https://pubmed.ncbi.nlm.nih.gov/30976429 30976429]|[https://pubmed.ncbi.nlm.nih.gov/29091730 29091730]|[https://pubmed.ncbi.nlm.nih.gov/27770796 27770796]|[https://pubmed.ncbi.nlm.nih.gov/31330771 31330771]|[https://pubmed.ncbi.nlm.nih.gov/31138570 31138570]|[https://pubmed.ncbi.nlm.nih.gov/27154587 27154587]|[https://pubmed.ncbi.nlm.nih.gov/31542553 31542553]|[https://pubmed.ncbi.nlm.nih.gov/30519059 30519059]|[https://pubmed.ncbi.nlm.nih.gov/30590504 30590504]|[https://pubmed.ncbi.nlm.nih.gov/25880997 25880997]|[https://pubmed.ncbi.nlm.nih.gov/27490501 27490501]|[https://pubmed.ncbi.nlm.nih.gov/29981456 29981456]|[https://pubmed.ncbi.nlm.nih.gov/28559273 28559273]|[https://pubmed.ncbi.nlm.nih.gov/28193652 28193652]|[https://pubmed.ncbi.nlm.nih.gov/26638216 26638216]|[https://pubmed.ncbi.nlm.nih.gov/25897818 25897818]|[https://pubmed.ncbi.nlm.nih.gov/26238337 26238337]|[https://pubmed.ncbi.nlm.nih.gov/19553129 19553129]|[https://pubmed.ncbi.nlm.nih.gov/29644540 29644540]|[https://pubmed.ncbi.nlm.nih.gov/26242685 26242685]|[https://pubmed.ncbi.nlm.nih.gov/28487556 28487556]|[https://pubmed.ncbi.nlm.nih.gov/32622213 32622213]|[https://pubmed.ncbi.nlm.nih.gov/30248413 30248413]|[https://pubmed.ncbi.nlm.nih.gov/24762211 24762211]|[https://pubmed.ncbi.nlm.nih.gov/11451678 11451678]|[https://pubmed.ncbi.nlm.nih.gov/33169865 33169865]|[https://pubmed.ncbi.nlm.nih.gov/11897589 11897589]|[https://pubmed.ncbi.nlm.nih.gov/31479607 31479607] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27834790 27834790]|[https://pubmed.ncbi.nlm.nih.gov/31523406 31523406]|[https://pubmed.ncbi.nlm.nih.gov/29978304 29978304]|[https://pubmed.ncbi.nlm.nih.gov/29575185 29575185]|[https://pubmed.ncbi.nlm.nih.gov/27326514 27326514]|[https://pubmed.ncbi.nlm.nih.gov/29029114 29029114]|[https://pubmed.ncbi.nlm.nih.gov/32450200 32450200]|[https://pubmed.ncbi.nlm.nih.gov/29432937 29432937]|[https://pubmed.ncbi.nlm.nih.gov/31906402 31906402]|[https://pubmed.ncbi.nlm.nih.gov/28739428 28739428]|[https://pubmed.ncbi.nlm.nih.gov/29298123 29298123]|[https://pubmed.ncbi.nlm.nih.gov/30976429 30976429]|[https://pubmed.ncbi.nlm.nih.gov/29091730 29091730]|[https://pubmed.ncbi.nlm.nih.gov/27770796 27770796]|[https://pubmed.ncbi.nlm.nih.gov/31330771 31330771]|[https://pubmed.ncbi.nlm.nih.gov/31138570 31138570]|[https://pubmed.ncbi.nlm.nih.gov/27154587 27154587]|[https://pubmed.ncbi.nlm.nih.gov/31542553 31542553]|[https://pubmed.ncbi.nlm.nih.gov/30519059 30519059]|[https://pubmed.ncbi.nlm.nih.gov/30590504 30590504]|[https://pubmed.ncbi.nlm.nih.gov/25880997 25880997]|[https://pubmed.ncbi.nlm.nih.gov/27490501 27490501]|[https://pubmed.ncbi.nlm.nih.gov/29981456 29981456]|[https://pubmed.ncbi.nlm.nih.gov/28559273 28559273]|[https://pubmed.ncbi.nlm.nih.gov/28193652 28193652]|[https://pubmed.ncbi.nlm.nih.gov/26638216 26638216]|[https://pubmed.ncbi.nlm.nih.gov/25897818 25897818]|[https://pubmed.ncbi.nlm.nih.gov/26238337 26238337]|[https://pubmed.ncbi.nlm.nih.gov/19553129 19553129]|[https://pubmed.ncbi.nlm.nih.gov/29644540 29644540]|[https://pubmed.ncbi.nlm.nih.gov/26242685 26242685]|[https://pubmed.ncbi.nlm.nih.gov/28487556 28487556]|[https://pubmed.ncbi.nlm.nih.gov/32622213 32622213]|[https://pubmed.ncbi.nlm.nih.gov/30248413 30248413]|[https://pubmed.ncbi.nlm.nih.gov/24762211 24762211]|[https://pubmed.ncbi.nlm.nih.gov/11451678 11451678]|[https://pubmed.ncbi.nlm.nih.gov/33169865 33169865]|[https://pubmed.ncbi.nlm.nih.gov/11897589 11897589]|[https://pubmed.ncbi.nlm.nih.gov/31479607 31479607] <br> | ||
'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br> | '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br> | ||
'''term_xref''' : GTC:G22418PV |GlycoEpitope:EP0019|CID: | '''term_xref''' : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br> | '''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br> | ||
| Line 563: | Line 563: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80722US G80722US] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80722US G80722US] <br> | ||
'''term_in_sentence''' : The cognate ligands for L-selectin possess the unusual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3][SO(3)-->6]GlcNAc).[PMID:[https://pubmed.ncbi.nlm.nih.gov/11331001 11331001]] <br> | '''term_in_sentence''' : The cognate ligands for L-selectin possess the unusual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3][SO(3)-->6]GlcNAc).[PMID:[https://pubmed.ncbi.nlm.nih.gov/11331001 11331001]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11331001 11331001]|[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11331001 11331001]|[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]| [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/15972893 15972893]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/22691873 22691873]|[https://pubmed.ncbi.nlm.nih.gov/18652681 18652681]|[https://pubmed.ncbi.nlm.nih.gov/9722682 9722682]|[https://pubmed.ncbi.nlm.nih.gov/10435581 10435581]|[https://pubmed.ncbi.nlm.nih.gov/19359410 19359410]|[https://pubmed.ncbi.nlm.nih.gov/15228275 15228275]|[https://pubmed.ncbi.nlm.nih.gov/18250165 18250165]|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]|[https://pubmed.ncbi.nlm.nih.gov/17944600 17944600]|[https://pubmed.ncbi.nlm.nih.gov/10460836 10460836]|[https://pubmed.ncbi.nlm.nih.gov/27993973 27993973]|[https://pubmed.ncbi.nlm.nih.gov/19149511 19149511]|[https://pubmed.ncbi.nlm.nih.gov/19150806 19150806]|[https://pubmed.ncbi.nlm.nih.gov/17172261 17172261]|[https://pubmed.ncbi.nlm.nih.gov/17142960 17142960]|[https://pubmed.ncbi.nlm.nih.gov/27956273 27956273]|[https://pubmed.ncbi.nlm.nih.gov/7578028 7578028]|[https://pubmed.ncbi.nlm.nih.gov/22260995 22260995]|[https://pubmed.ncbi.nlm.nih.gov/24519996 24519996]|[https://pubmed.ncbi.nlm.nih.gov/21596021 21596021]|[https://pubmed.ncbi.nlm.nih.gov/21982762 21982762]|[https://pubmed.ncbi.nlm.nih.gov/21775439 21775439]|[https://pubmed.ncbi.nlm.nih.gov/17334369 17334369]|[https://pubmed.ncbi.nlm.nih.gov/9710564 9710564]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/16227985 16227985]|[https://pubmed.ncbi.nlm.nih.gov/11895802 11895802]|[https://pubmed.ncbi.nlm.nih.gov/22750968 22750968]|[https://pubmed.ncbi.nlm.nih.gov/15157883 15157883]|[https://pubmed.ncbi.nlm.nih.gov/19067429 19067429] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000027|GlycoEpitope:EP0015|CID: | '''term_xref''' : GlycoMotif:GGM.000027|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628<br> | ||
'''synonyms''' : 6-sulfo SLex|6-Sulfo-sialyl Lewis x|6-sulfo SLe^x <br> | '''synonyms''' : 6-sulfo SLex|6-Sulfo-sialyl Lewis x|6-sulfo SLe^x <br> | ||
'''function''' : lymphocyte homing[GlycoEpitope:EP0015]<br> | '''function''' : lymphocyte homing[GlycoEpitope:EP0015]<br> | ||
| Line 597: | Line 597: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/4041428 4041428]|[https://pubmed.ncbi.nlm.nih.gov/5686860 5686860]<br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/4041428 4041428]|[https://pubmed.ncbi.nlm.nih.gov/5686860 5686860]<br> | ||
'''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine. Corresponds to a partial structure of blood group A type 1 oligosaccharide.[CHEBI:62988]<br> | '''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine. Corresponds to a partial structure of blood group A type 1 oligosaccharide.[CHEBI:62988]<br> | ||
'''term_xref''' : GlycoMotif:GGM.000047|CID: | '''term_xref''' : GlycoMotif:GGM.000047|CID:53477630|CHEBI:62988|GlycoEpitope:EP0260<br> | ||
'''synonyms''' : Blood Group A Type 1 (difucosyl)|ALe^b|A-Leb|A-Le^b|A Lewis b<br> | '''synonyms''' : Blood Group A Type 1 (difucosyl)|ALe^b|A-Leb|A-Le^b|A Lewis b<br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 646: | Line 646: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000041|GTC:G62735WZ|CID: | '''term_xref''' : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 661: | Line 661: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] <br> | '''term_in_sentence''' : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25738328 25738328]|[https://pubmed.ncbi.nlm.nih.gov/31102247 31102247]|[https://pubmed.ncbi.nlm.nih.gov/26982439 26982439]|[https://pubmed.ncbi.nlm.nih.gov/31685194 31685194]|[https://pubmed.ncbi.nlm.nih.gov/29197571 29197571]|[https://pubmed.ncbi.nlm.nih.gov/29182521 29182521]|[https://pubmed.ncbi.nlm.nih.gov/25725011 25725011]| [https://pubmed.ncbi.nlm.nih.gov/27787767 27787767]|[https://pubmed.ncbi.nlm.nih.gov/21736263 21736263]|[https://pubmed.ncbi.nlm.nih.gov/25300540 25300540]|[https://pubmed.ncbi.nlm.nih.gov/30840869 30840869]|[https://pubmed.ncbi.nlm.nih.gov/25081074 25081074]|[https://pubmed.ncbi.nlm.nih.gov/28250359 28250359]| [https://pubmed.ncbi.nlm.nih.gov/29763421 29763421]|[https://pubmed.ncbi.nlm.nih.gov/29910219 29910219]|[https://pubmed.ncbi.nlm.nih.gov/20161969 20161969]|[https://pubmed.ncbi.nlm.nih.gov/32019265 32019265]| [https://pubmed.ncbi.nlm.nih.gov/30879650 30879650]| [https://pubmed.ncbi.nlm.nih.gov/12587986 12587986]|[https://pubmed.ncbi.nlm.nih.gov/29773374 29773374]|[https://pubmed.ncbi.nlm.nih.gov/31376451 31376451]| [https://pubmed.ncbi.nlm.nih.gov/10906950 10906950]|[https://pubmed.ncbi.nlm.nih.gov/26096004 26096004]|[https://pubmed.ncbi.nlm.nih.gov/25595947 25595947]| [https://pubmed.ncbi.nlm.nih.gov/21673932 21673932]|[https://pubmed.ncbi.nlm.nih.gov/29452181 29452181]|[https://pubmed.ncbi.nlm.nih.gov/24083454 24083454]|[https://pubmed.ncbi.nlm.nih.gov/10856926 10856926]|[https://pubmed.ncbi.nlm.nih.gov/22732132 22732132]| [https://pubmed.ncbi.nlm.nih.gov/18657571 18657571]|[https://pubmed.ncbi.nlm.nih.gov/29175166 29175166]|[https://pubmed.ncbi.nlm.nih.gov/28842199 28842199]|[https://pubmed.ncbi.nlm.nih.gov/27592817 27592817]| [https://pubmed.ncbi.nlm.nih.gov/27302593 27302593]| [https://pubmed.ncbi.nlm.nih.gov/27339323 27339323]| [https://pubmed.ncbi.nlm.nih.gov/12705640 12705640]|[https://pubmed.ncbi.nlm.nih.gov/31635752 31635752]| [https://pubmed.ncbi.nlm.nih.gov/31063786 31063786]|[https://pubmed.ncbi.nlm.nih.gov/31151236 31151236]|[https://pubmed.ncbi.nlm.nih.gov/25940531 25940531]|[https://pubmed.ncbi.nlm.nih.gov/26093316 26093316]|[https://pubmed.ncbi.nlm.nih.gov/28962761 28962761]|[https://pubmed.ncbi.nlm.nih.gov/28093332 28093332]| [https://pubmed.ncbi.nlm.nih.gov/30875044 30875044]|[https://pubmed.ncbi.nlm.nih.gov/27723949 27723949]|[https://pubmed.ncbi.nlm.nih.gov/28119189 28119189]|[https://pubmed.ncbi.nlm.nih.gov/30600008 30600008]|[https://pubmed.ncbi.nlm.nih.gov/25081085 25081085]|[https://pubmed.ncbi.nlm.nih.gov/21673932 21673932] <br> | ||
'''definition''' : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] <br> | '''definition''' : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] <br> | ||
'''term_xref''' : CHEBI:17029<br> | '''term_xref''' : CHEBI:17029<br> | ||
| Line 682: | Line 682: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000041|GTC:G62735WZ|CID: | '''term_xref''' : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 697: | Line 697: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] <br> | '''term_in_sentence''' : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25738328 25738328]|[https://pubmed.ncbi.nlm.nih.gov/31102247 31102247]|[https://pubmed.ncbi.nlm.nih.gov/26982439 26982439]|[https://pubmed.ncbi.nlm.nih.gov/31685194 31685194]|[https://pubmed.ncbi.nlm.nih.gov/29197571 29197571]|[https://pubmed.ncbi.nlm.nih.gov/29182521 29182521]|[https://pubmed.ncbi.nlm.nih.gov/25725011 25725011]|[https://pubmed.ncbi.nlm.nih.gov/27787767 27787767]|[https://pubmed.ncbi.nlm.nih.gov/21736263 21736263]|[https://pubmed.ncbi.nlm.nih.gov/25300540 25300540]|[https://pubmed.ncbi.nlm.nih.gov/30840869 30840869]|[https://pubmed.ncbi.nlm.nih.gov/25081074 25081074]|[https://pubmed.ncbi.nlm.nih.gov/28250359 28250359]| [https://pubmed.ncbi.nlm.nih.gov/29763421 29763421]|[https://pubmed.ncbi.nlm.nih.gov/29910219 29910219]|[https://pubmed.ncbi.nlm.nih.gov/20161969 20161969]|[https://pubmed.ncbi.nlm.nih.gov/32019265 32019265]|[https://pubmed.ncbi.nlm.nih.gov/30879650 30879650]|[https://pubmed.ncbi.nlm.nih.gov/12587986 12587986]|[https://pubmed.ncbi.nlm.nih.gov/29773374 29773374]|[https://pubmed.ncbi.nlm.nih.gov/31376451 31376451]| [https://pubmed.ncbi.nlm.nih.gov/10906950 10906950]| [https://pubmed.ncbi.nlm.nih.gov/26096004 26096004]|[https://pubmed.ncbi.nlm.nih.gov/25595947 25595947]|[https://pubmed.ncbi.nlm.nih.gov/21673932 21673932]|[https://pubmed.ncbi.nlm.nih.gov/29452181 29452181]| [https://pubmed.ncbi.nlm.nih.gov/24083454 24083454]|[https://pubmed.ncbi.nlm.nih.gov/10856926 10856926]|[https://pubmed.ncbi.nlm.nih.gov/22732132 22732132]|[https://pubmed.ncbi.nlm.nih.gov/18657571 18657571]|[https://pubmed.ncbi.nlm.nih.gov/29175166 29175166]|[https://pubmed.ncbi.nlm.nih.gov/28842199 28842199]| [https://pubmed.ncbi.nlm.nih.gov/27592817 27592817]|[https://pubmed.ncbi.nlm.nih.gov/27302593 27302593]|[https://pubmed.ncbi.nlm.nih.gov/27339323 27339323]|[https://pubmed.ncbi.nlm.nih.gov/12705640 12705640]| [https://pubmed.ncbi.nlm.nih.gov/31635752 31635752]| [https://pubmed.ncbi.nlm.nih.gov/31063786 31063786]|[https://pubmed.ncbi.nlm.nih.gov/31151236 31151236]|[https://pubmed.ncbi.nlm.nih.gov/25940531 25940531]|[https://pubmed.ncbi.nlm.nih.gov/26093316 26093316]|[https://pubmed.ncbi.nlm.nih.gov/28962761 28962761]|[https://pubmed.ncbi.nlm.nih.gov/28093332 28093332]|[https://pubmed.ncbi.nlm.nih.gov/30875044 30875044]|[https://pubmed.ncbi.nlm.nih.gov/27723949 27723949]|[https://pubmed.ncbi.nlm.nih.gov/28119189 28119189]|[https://pubmed.ncbi.nlm.nih.gov/30600008 30600008]|[https://pubmed.ncbi.nlm.nih.gov/25081085 25081085]| [https://pubmed.ncbi.nlm.nih.gov/21673932 21673932]<br> | ||
'''definition''' : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] <br> | '''definition''' : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029] <br> | ||
'''term_xref''' : CHEBI:17029 <br> | '''term_xref''' : CHEBI:17029 <br> | ||
Revision as of 17:17, 12 April 2023
GSD000151
term (main_entry) : Sialyl Lewis x
glycan_dictionary_accession : GSD000151
glytoucan_accession : G00054MO
term_in_sentence : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:12828079]
publication : 12828079|8940172|10075923|19054801|9642161|31054033|15229399|29061785|16033070|10728707|9556613| 8940172|9298692|18607721|22593503|25944902| 9642161|15780091|20401888
definition : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH: 2030970],CHEI:71622
term_xref : GTC:G00054MO |GlycoEpitope:EP0012|CID: 44456859|CHEBI:71622|MESH: 2030970|GlycoMotif:GGM.000022
synonyms : SLe(x)|SLe^x|SLex|Slex
function : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012]
disease_associations : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012]
wikipedia :
essentials_of_glycobiology :
GSD000152
term (main_entry) : Sialyl Lewis x-i
glycan_dictionary_accession : GSD000152
glytoucan_accession : G06597DS
term_in_sentence : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:9815711]
publication : 9815711|9730796|11867833|9713476|2819663|9372327|9615762|1352835|2575680|9330526|8753037|2210805|12680155|11974864|10453898|2565704|17144590
definition :
term_xref : GTC:G06597DS|GlycoEpitope:EP0043|CID: 91855346|CHEBI:147019
synonyms :
function : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043]
disease_associations : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043]
wikipedia :
essentials_of_glycobiology :
GSD000153
term (main_entry) : Sialyl T antigen
glycan_dictionary_accession : GSD000153
glytoucan_accession : G65562ZE
term_in_sentence : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:32583304]
publication : 32583304|31897478|31719620|10365852|25727149|11523928|20407596|25464017|30864133|26391208|19811634|29796594|23725156|8905873|11192238|18275089|27037304|11949946|15604091|24118321
definition : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257]
term_xref : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000154
term (main_entry) : Sialylated biantennary
glycan_dictionary_accession : GSD000154
glytoucan_accession :
term_in_sentence : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:23115267]
publication : 23115267|31510952|29265394|31589880|3979568|26045275|29029079|30252064
definition : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN]
term_xref :
synonyms : sialyl biantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000155
term (main_entry) : Sialylated complex-type
glycan_dictionary_accession : GSD000155
glytoucan_accession :
term_in_sentence : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:1694115]
publication : 1694115|15201278|30471292|30969765|11058758|28342150
definition : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues.
term_xref :
synonyms : sialo-complex type
function : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: 15201278] Appears in IgG-Fc.[PMID:20647032 ]
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 10
GSD000156
term (main_entry) : Sialylated tetraantennary
glycan_dictionary_accession : GSD000156
glytoucan_accession :
term_in_sentence : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:16321355]
publication : 16321355| 1940447| 27501865
definition : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000157
term (main_entry) : Sialyl-Tn antigen
glycan_dictionary_accession : GSD000157
glytoucan_accession : G36123IU
term_in_sentence : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:23035012]
publication : 23035012|29273237|15770530|31595388|26617889|1720922|15466199|10971172|14652017|8616877|1543361|16965854|21566901|9269833|9834267|24970145| 22367369| 10778170|30018351|28628803| 16149605|32134186|28632300|11308020| 10365852|17195456|23567325|11014575|2342728|8575847|1851822|11735169|20960853|7846011
definition : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818]
term_xref : GTC:G36123IU|GlycoEpitope:EP0022|CID: 51351800|CHEBI:61818
synonyms :
function : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022]
disease_associations : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022]
wikipedia :
essentials_of_glycobiology : Chapter 56
GSD000158
term (main_entry) : SLex Core 2 O-glycan
glycan_dictionary_accession : GSD000158
glytoucan_accession : G97345NY
term_in_sentence : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:15596301]
publication : 15596301
definition :
term_xref : GlycoMotif:GGM.000053|GTC:G97345NY
synonyms : SLe^x Core 2 O-glycan
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000159
term (main_entry) : SSEA-1
glycan_dictionary_accession : GSD000159
glytoucan_accession : G85497PI
term_in_sentence : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:27550342]
publication : 27550342|25564944|30987116|10778174|19427293|24923741|28092949|16499901|10470652|18787210|2885312|16149609|17003364|27363517|15505339|27990704|2568298|20491542|23572256|1977666|9553168| 20458727|2566639|14577357|20960856|15547746|9096265|30639212|1357195|1359630|20181261|20508065|2907526|22624699|22988836|17183690|27188587|7908065|10400391|6137429|1979260|2898921|14736812|30919971
definition :
term_xref : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343
synonyms :
function : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042]
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 10
GSD000160
term (main_entry) : SSEA-3
glycan_dictionary_accession : GSD000160
glytoucan_accession : G25129BT
term_in_sentence : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926]
publication : 31817926|30271856|32684574|26677875|23175153|32525407|29227830|18773292|25561682|10837462| 2412924|21149348|17008424| 2874662|25171543|31304790|31642560|30484221|30525067|21161592|27325407|28170296|29637816|27318475|31346146|7648586|24236059|21964054|27456773|30558911|21559451|29312455|27549315|30599359|6141938|28883415|30733757|26041528|16643871
definition : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071]
term_xref : GTC:G25129BT|GlycoEpitope:EP0039|CID: 91855781|CHEBI:149071|GlycoMotif:GGM.000079
synonyms :
function :
disease_associations : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039]
wikipedia :
essentials_of_glycobiology :
GSD000161
term (main_entry) : SSEA-4
glycan_dictionary_accession : GSD000161
glytoucan_accession : G84263XI
term_in_sentence : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:31817926]
publication : 27845370|31817926|26295543|25171543|25978997|30296654|25853231|24862940|31243630|28736232|22895512|24578244|29478902|23574147|23768762|27797400| 29227830|18773292|25123923|22924692|22665977|23330736|31831622|31916611| 2412924|16033656|24866102| 20458727| 21149348|26940129| 17008424|2874662|23301556|27836003|19118716|24550271|32988880|22743677|20683402|17062733|23570331|30310530|31545316|23509763|24364909|18273440|28985528|22266579
definition :
term_xref : GTC:G84263XI|GlycoEpitope:EP0044|CID:91845478|CHEBI:154843
synonyms :
function :
disease_associations : teratocarcinoma[GlycoEpitope:EP0044]
wikipedia :
essentials_of_glycobiology : Chapter 47
GSD000162
term (main_entry) : Sulfatide
glycan_dictionary_accession : GSD000162
glytoucan_accession : G72548RZ
term_in_sentence : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:23550344]
publication : 23550344|18465098|26542149|15158666|10434709|22619219|29676479|30196830|16143863|1052451|30400820|29887538|26981544|17986152|31739035|19941861|24578319|30531843|25645724|31197846|22821828|27861899|31037952|23593400|23604989|17855742|25966258|25989600|9657940|29497057|12838515|25170267|9878314|20554435|1410493|26585924|17257892|17044925|21089387|11445552|22977233|21437360|17179664|6273571|8370675
definition :
term_xref : GlycoMotif:GGM.000063|GTC:G72548RZ
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 47
GSD000163
term (main_entry) : T antigen
glycan_dictionary_accession : GSD000163
glytoucan_accession : G00031MO
term_in_sentence : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419]
publication : 723127|19505650|31527246|28113048|25868857|26731525|22994493|3849428|25589241|12709866|26615524|26136575|19671663|18551603|11160729|22261839|30758913|25681708|29113555|24998850|1654819|28039910|29206210|32404521|10555041|26517398|2446015|2998768|3026642|18812503|6092664|2153691|8709258|3009889|15109748| 12709866|31787742|27433780|26017382|24048785|26735515|9224657|26061652|29343574| 25681708|23805194|26751495|22023388|15381338|8249277|3023660|25866902
definition : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820]
term_xref : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009
synonyms : TF antigen
function : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020]
disease_associations : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020]
wikipedia :
essentials_of_glycobiology : Chapter 47
GSD000164
term (main_entry) : Tetraantennary
glycan_dictionary_accession : GSD000164
glytoucan_accession :
term_in_sentence : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:24308486]
publication : 24308486|17951374|28880909|9177699|9760189|12322961|20129637|2492275|3402460|2361735|6525453|27730440|2551687|25365149|9751793|29875690|29479898|9134426|30943309|3546284|29888905|30624066|30537828|31110965|29311294|12852965|3015940|1907570|29137999|29359131|29858715|30295034|31829566|8381405|26929217|20662591|30612270|3089784|28186213|3427034|26763099|27354006|24991291|7496138|1940447|11114588|29031301|9448855|3979385|27722599|31126011|28002670|28991403|24032650|15316281|25154914|22490318|22430811|1463783|18803208|7881173|7697655|7240157|1768292
definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref :
synonyms :
function :
disease_associations :
wikipedia : https://www.wikidata.org/wiki/Q27104888
essentials_of_glycobiology :
GSD000165
term (main_entry) : Tetraantennary complex-type
glycan_dictionary_accession : GSD000165
glytoucan_accession :
term_in_sentence : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID:1899031]
publication : 1899031|8251489|8274017| 1899031| 6317691|23668542| 6088518|21495009|1457971|1783599|10988252|11425798|7522229|2574992|3730425|10200178|2939068|21584695| 7524670|7682847|2930192|1726466|9881746|11068879|6704968|2302846| 24032650| 15316281|11051207|10220588|2813359|2174368|21755550|3571208|1929437|3681300|6581225|3364983|2902877|2297756|1315684|6830758|1998670
definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 10
GSD000166
term (main_entry) : Tetrasialylated diantennary
glycan_dictionary_accession : GSD000166
glytoucan_accession :
term_in_sentence : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:1997323]
publication : 1997323
definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000167
term (main_entry) : Tn antigen
glycan_dictionary_accession : GSD000167
glytoucan_accession : G57321FI
term_in_sentence : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914]
publication : 27679419|31938254|30637914|24643043|31225574|21259410|31742337|28514044|33014816|28708980|27432485|33050853|26045765|27542280|24411673|27760846|30115016|1410473|29802864|29669308|29251002|32541028|31019509|1582597|2981150|10842187|29638123| 22367369|10778170|1510031|19372570|20641477| 16149605|15770530|27856425|23814067|28068458| 32134186|8174100|10571017|27453399|1727666|23740330
definition : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212]
term_xref : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008
synonyms :
function : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021]
disease_associations : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021].
wikipedia :
essentials_of_glycobiology :
GSD000168
term (main_entry) : Triantennary
glycan_dictionary_accession : GSD000168
glytoucan_accession :
term_in_sentence : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960]
publication : 24992960|27025342|29642865|29456020|26914862|26926155|26299345|28981809|18395704|2211710|23461434|18327885|15264862|22954207|9061362|16581187|26537865|3979568|28129130|7679920|8068017|7783116|3857231|20540518|1706936|2430615|8078981|2211711|6767476|3814128|2597120|7451505|8204583|20619452|10460831|1924399|6643471|31809011|30042045|2477056|7882496|2430614| 2551687|2426141|2065052|28988716|31144994|26966183|29809215
definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000169
term (main_entry) : Triantennary complex
glycan_dictionary_accession : GSD000169
glytoucan_accession :
term_in_sentence : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998]
publication : 9118998|9061362|18395704|3814128|7451505|10460831|26926155|26966183|16581187|16973123|8204583|29809215|11114588|31322324|15044389|16372382| 8251489|8299583|1555586|7509658|1569060|16261636
definition : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252] Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.
term_xref : CHEBI:156252
synonyms : Triantennary complex-type
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 10
GSD000170
term (main_entry) : Triantennary N-glycans
glycan_dictionary_accession : GSD000170
glytoucan_accession :
term_in_sentence : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163]
publication : 29399163|22325877|18439991|24873509|11454001
definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000171
term (main_entry) : Triantennary sialylated
glycan_dictionary_accession : GSD000171
glytoucan_accession :
term_in_sentence : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129]
publication : 18642129|31964828|3979568|27936604|23681398|21538882|7579793|7613477|2223825|3539023|3674882
definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues.
term_xref :
synonyms :
function : Appears in human serotransferrin.[PMID: 3979568]
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000172
term (main_entry) : Triantennary trisialylated fucosylated
glycan_dictionary_accession : GSD000172
glytoucan_accession :
term_in_sentence : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:17591618]
publication : 17591618
definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000173
term (main_entry) : Trifucosyl Lewis b antigen
glycan_dictionary_accession : GSD000173
glytoucan_accession : G74578MX
term_in_sentence : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:1735443]
publication : 1735443
definition : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783]
term_xref : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783
synonyms : trifucosyl-Leb antigen
function : cancer-associated antigen[GlycoEpitope: EP0092]
disease_associations : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092]
wikipedia :
essentials_of_glycobiology :
GSD000174
term (main_entry) : Trifucosyl lewis y
glycan_dictionary_accession : GSD000174
glytoucan_accession : G74917JX
term_in_sentence : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:3733752]
publication : 3733752|2426269
definition : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332]
term_xref : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332
synonyms : trifucosyl Ley
function :
disease_associations : colonic adenocarcinomia[GlycoEpitope: EP0094]
wikipedia :
essentials_of_glycobiology :
GSD000175
term (main_entry) : Trimannosyl core
glycan_dictionary_accession : GSD000175
glytoucan_accession :
term_in_sentence : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567]
publication : 18320567|27629418|26514868|26821880|2477227|6213618|31747570|29273674|31064325|1291063|28353332|1421754|29666272|11421342|15648688|28179475|28903882|27189951|9455915|22768188|9254048|8721739|2249985|22933239|25629585|24489949|2981047|11067815|1729985|1710649|16672288|2719668|19003000|23025485|22500028|10409642|1325461|23136055|23085445|21656680|22448293|22132163|1425696|20696712|18056652|15084511|18633282|15814299
definition : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000176
term (main_entry) : Trisialylated
glycan_dictionary_accession : GSD000176
glytoucan_accession :
term_in_sentence : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709]
publication : 6469957|18818422|18332077|21138277|9136890|10782293|19841910|20067809|14751029|8797382|16877748|19131698|20578731|24669823|22426998|27501865|2121479|24663386|32209427|32737218|33245334|26927318|30962676|28370937|30194503|26321095|30463578|31455764|31566965|31266306|29782424|31247951|30487799|2049094|1997323|10913832
definition : A glycan with three sialic acid components.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000177
term (main_entry) : Trisialylated complex-type oligosaccharide-alditols
glycan_dictionary_accession : GSD000177
glytoucan_accession :
term_in_sentence : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205]
publication : 3571205
definition :
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000178
term (main_entry) : Trisialylated diantennary
glycan_dictionary_accession : GSD000178
glytoucan_accession :
term_in_sentence : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:1997323]
publication : 1997323
definition : A diantennary/biantennary glycans with three sialic acid components.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000179
term (main_entry) : Trisialylated triantennary
glycan_dictionary_accession : GSD000179
glytoucan_accession :
term_in_sentence : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648]
publication : 30194503| 27501865 |10998266|20578731|17591618|14751029|18818422|8942648|8900952
definition : A triantennry glycan with three sialic acid components.
term_xref :
synonyms :
function :
disease_associations :
essentials_of_glycobiology :
GSD000180
term (main_entry) : VIM-2
glycan_dictionary_accession : GSD000180
glytoucan_accession : G22418PV
term_in_sentence : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317]
publication : 27834790|31523406|29978304|29575185|27326514|29029114|32450200|29432937|31906402|28739428|29298123|30976429|29091730|27770796|31330771|31138570|27154587|31542553|30519059|30590504|25880997|27490501|29981456|28559273|28193652|26638216|25897818|26238337|19553129|29644540|26242685|28487556|32622213|30248413|24762211|11451678|33169865|11897589|31479607
definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946]
term_xref : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033
synonyms :
function : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019]
disease_associations : chronic myelogenous leukemia.[GlycoEpitope:EP0019]
wikipedia :
essentials_of_glycobiology :
GSD000181
term (main_entry) : N-acetyllactosamine (Type 1)
glycan_dictionary_accession : GSD000181
glytoucan_accession : G00056MO
term_in_sentence : The N-acetyllactosamine type 1 (LacNAc type 1, Galβ1,3GlcNAc) is a well-known precursor of several important blood group epitopes, such as Lewis A, Lewis B, or sialyl Lewis A [1], which are involved in many biological processes, e.g., fertilization [2] and pathogen adhesion [3]. [PMID:28796164]
publication : 28796164|28167527
definition :
term_xref : GTC:G00056MO|GlycoMotif:GGM.000005
synonyms : LacNAc type 1|Type 1 LN|Type-1 lactosamine
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000182
term (main_entry) : Polysialic acid
glycan_dictionary_accession : GSD000182
glytoucan_accession :
term_in_sentence : Polysialic acid (PSA) is a carbohydrate composed of a linear polymer of α2,8-linked sialic acids, primarily attached to the Neural Cell Adhesion Molecule (NCAM). [PMID:36076963]
publication : 36076963|35222358
definition :
term_xref : GlycoMotif:GGM.000252
synonyms : polySia|PSA
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000183
term (main_entry) : Hyaluronan
glycan_dictionary_accession : GSD000183
glytoucan_accession : G29086KO
term_in_sentence : Hyaluronan (HA) comprises a major component of the extracellular matrix (ECM) in vertebrate connective tissues and is abundant in the cartilage, skin, brain, vitreous body, umbilical cord, and synovial fluid. [PMID:33171800]
publication : 33171800|34209222
definition :
term_xref : GTC:G29086KO
synonyms : HA
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000184
term (main_entry) : Chondroitin sulfate/dermatan sulfate
glycan_dictionary_accession : GSD000184
glytoucan_accession :
term_in_sentence : Heparan sulfate (HS) and chondroitin sulfate/dermatan sulfate (CS/DS) proteoglycans are heavily glycosylated proteins, crucial for animal development and homeostasis. [PMID:35192612]
publication : 35192612|35425970
definition :
term_xref :
synonyms : CS/DS|chondroitin/dermatan sulfate
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000185
term (main_entry) : Heparan sulfate/heparin
glycan_dictionary_accession : GSD000185
glytoucan_accession :
term_in_sentence : Heparan sulfate (HS)/heparin is a structurally complex class of glycosaminoglycans (GAGs) that have been implicated in a wide range of biological activities. [PMID:31016560]
publication : 23313092|31016560|23152789
definition :
term_xref :
synonyms : HS/heparin|heparan sufate (HS)/heparin|H/HS
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000186
term (main_entry) : Core 1
glycan_dictionary_accession : GSD000186
glytoucan_accession : G00031MO
term_in_sentence : O-glycans are initiated by the addition of GalNAc to serine or threonine (via the ppGalNAcT family of glycosyltransferases), forming the Tn antigen (GalNAcα-O-Ser/Thr), which is used to generate the core 1 structure (Galβ1,3GalNAcα-O-Ser/Thr) on which most complex and branched O-glycans are derived. [PMID:31645367]
publication : 31645367|32297877
definition :
term_xref : GTC:G00031MO|GlycoMotif:GGM.001005
synonyms : C1G
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000187
term (main_entry) : Blood group A (Type 3)
glycan_dictionary_accession : GSD000187
glytoucan_accession : G99315PE
term_in_sentence :
publication : 7800218|17998569|19756298|3191504
definition :
term_xref : GlycoMotif:GGM.000011|GTC:G99315PE
synonyms : A type 3 antigen|blood group A type 3|A antigen (type 3)
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 14
GSD000188
term (main_entry) : 6-Sulfo Sialyl Lewis x
glycan_dictionary_accession : GSD000188
glytoucan_accession : G80722US
term_in_sentence : The cognate ligands for L-selectin possess the unusual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3][SO(3)-->6]GlcNAc).[PMID:11331001]
publication : 11331001|2288521|26137907|9400621| 9556613|15972893|9015359|22691873|18652681|9722682|10435581|19359410|15228275|18250165|10536036|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|14593101|16227985|11895802|22750968|15157883|19067429
definition :
term_xref : GlycoMotif:GGM.000027|GlycoEpitope:EP0015|CID:70698321|CHEBI:71628
synonyms : 6-sulfo SLex|6-Sulfo-sialyl Lewis x|6-sulfo SLe^x
function : lymphocyte homing[GlycoEpitope:EP0015]
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 34|Chapter 35
GSD000189
term (main_entry) : Blood group B (Type 1) - Lewis b
glycan_dictionary_accession : GSD000189
glytoucan_accession : G89208KM
term_in_sentence : Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status. [PMID:2247887]
publication : 2247887|19756298|30831115
definition :
term_xref : GlycoMotif:GGM.000046
synonyms : Blood Group B, type 1 chain (Lewis b)|B-Leb|B-Le^b
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000190
term (main_entry) : Blood group A (Type 1) - Lewis b
glycan_dictionary_accession : GSD000190
glytoucan_accession : G97501MA
term_in_sentence : Ten monoclonal antibodies and one lectin were used to study the localization and distribution of Blood Group ABH, type 1 chain (Lewis a, Lewis b) and type 2 chain (H-2, Y) antigens in 22 cases of normal uterine cervix, with known ABO and Lewis phenotype and secretor status.[PMID:2247887]
publication : 2247887|19756298|4041428|5686860
definition : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine. Corresponds to a partial structure of blood group A type 1 oligosaccharide.[CHEBI:62988]
term_xref : GlycoMotif:GGM.000047|CID:53477630|CHEBI:62988|GlycoEpitope:EP0260
synonyms : Blood Group A Type 1 (difucosyl)|ALe^b|A-Leb|A-Le^b|A Lewis b
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000191
term (main_entry) : Sulfated LacdiNAc
glycan_dictionary_accession : GSD000191
glytoucan_accession : G18464VS
term_in_sentence : The mRNA expression of the enzymes related to the formation of sulfated LacdiNAc:β(1,4)-N-acetylgalactosaminyltransferases 3 (B4GALNT3) and 4 (B4GALNT4), carbohydrate sulfotransferases 8 (CHST8) and 9 (CHST9); and β(1,4)-galactosyltransferase 1 (B4GALT1) in these cells was confirmed by RT-PCR (Fig. S4).[PMID:31558607]
publication : 31558607|27318476|19756298|11279168|26688390
definition :
term_xref : GlycoMotif:GGM.000049
synonyms : 4'-O-sulfated LacdiNAc|4'-sulfated LDN|sulfated LDN
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000192
term (main_entry) : Sialylated LacdiNAc
glycan_dictionary_accession : GSD000192
glytoucan_accession : G55583HW
term_in_sentence : The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewisx), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewisx).[PMID:7592613]
publication : 7592613|34192302|19756298|16286643
definition :
term_xref : GlycoMotif:GGM.000050
synonyms : sialylated-LacdiNAc|Sialylated LDN
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Retired Terms (by Term Name)
A2
term (main_entry) : A2
glycan_dictionary_accession : GSD000015
glytoucan_accession : G62735WZ
term_in_sentence : Landsteiner ABO system of blood groups is most important for transfusion medicine and has subtypes of A Antigen, A1 and A2, upon which further groups of A and AB have been classified.[PMID:28658771]
publication : 29000000|28658771
definition :
term_xref : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
date retired : 01/27/2023
reason for retirement : Duplicated entry. See GSD000032.
Chitin
term (main_entry) : Chitin (This term has been retired.)
glycan_dictionary_accession : GSD000042
glytoucan_accession :
term_in_sentence : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241]
publication : 25738328|31102247|26982439|31685194|29197571|29182521|25725011| 27787767|21736263|25300540|30840869|25081074|28250359| 29763421|29910219|20161969|32019265| 30879650| 12587986|29773374|31376451| 10906950|26096004|25595947| 21673932|29452181|24083454|10856926|22732132| 18657571|29175166|28842199|27592817| 27302593| 27339323| 12705640|31635752| 31063786|31151236|25940531|26093316|28962761|28093332| 30875044|27723949|28119189|30600008|25081085|21673932
definition : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029]
term_xref : CHEBI:17029
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 26
date retired : 01/27/2023
reason for retirement : Not including linear polysaccharides to glycan structure dictionary.
Retired Terms (by Glycan Dictionary Accessions)
GSD000015
term (main_entry) : A2
glycan_dictionary_accession : GSD000015
glytoucan_accession : G62735WZ
term_in_sentence : Landsteiner ABO system of blood groups is most important for transfusion medicine and has subtypes of A Antigen, A1 and A2, upon which further groups of A and AB have been classified.[PMID:28658771]
publication : 29000000|28658771
definition :
term_xref : GlycoMotif:GGM.000041|GTC:G62735WZ|CID:91852328
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
date retired : 01/27/2023
reason for retirement : Duplicated entry. See GSD000032.
GSD000042
term (main_entry) : Chitin
glycan_dictionary_accession : GSD000042
glytoucan_accession :
term_in_sentence : In this review, we will focus on the prevalence and structural function of chitin in bacteria, fungi, and protists, with a particular focus on the evolution of chitin synthases and the function of chitin oligosaccharides as a signaling molecule in symbiosis and immunity[PMID: 31102241]
publication : 25738328|31102247|26982439|31685194|29197571|29182521|25725011|27787767|21736263|25300540|30840869|25081074|28250359| 29763421|29910219|20161969|32019265|30879650|12587986|29773374|31376451| 10906950| 26096004|25595947|21673932|29452181| 24083454|10856926|22732132|18657571|29175166|28842199| 27592817|27302593|27339323|12705640| 31635752| 31063786|31151236|25940531|26093316|28962761|28093332|30875044|27723949|28119189|30600008|25081085| 21673932
definition : An aminoglycan consisting of β-(1→4)-linked N-acetyl-D-glucosamine residues.[CHEBI:17029]
term_xref : CHEBI:17029
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 26
date retired : 01/27/2023
reason for retirement : Not including linear polysaccharides to glycan structure dictionary.
Submit new terms
If you feel that a term is missing, you can submit a single term using the online form found at https://data.glygen.org/gsd/ . To submit multiple terms you can use GlyGen file upload https://data.glygen.org/uploads. Template for submitting terms can be found here. Contact https://www.glygen.org/contact-us/ for any questions.